Bausch Health Companies Inc. (BHC)

Market Cap	2.98B
Revenue (ttm)	9.20B
Net Income (ttm)	-471.00M
Shares Out	367.10M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	2.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,043,283
Open	8.14
Previous Close	8.17
Day's Range	8.09 - 8.18
52-Week Range	3.96 - 11.46
Beta	0.77
Analysts	Hold
Price Target	6.63 (-18.25%)
Earnings Date	Oct 30, 2024

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas Appio
• Employees: 20,270
• Stock Exchange: NYSE
• Ticker Symbol: BHC
• Website: https://www.bauschhealth.com

Financial Performance

In 2023, Bausch Health Companies's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 163.1% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $6.63, which is a decrease of -18.25% from the latest price.

Price Target

$6.63

(-18.25% downside)

Analyst Consensus: Hold